Buprenorphine FAQ and Peer Discussion
Frequently asked questions about buprenorphine care; chapter in the Integration of Buprenorphine into HIV Primary Care document.
Frequently asked questions about buprenorphine care; chapter in the Integration of Buprenorphine into HIV Primary Care document.
NASTAD’s National AIDS Drug Assistance Program (ADAP) Formulary Database provides an online, searchable, publicly available resource detailing state-by-state ADAP coverage of medications, including HIV antiretroviral (ARV) treatments, “A1” Opportunistic Infections (A1 OI) medications, treatments for hepatitis B and C, mental health and substance use treatment medications, and various vaccines and laboratory tests.
Resource updated 03/07/2024
Resource updated 03/13/2024
U.S. HIV-related treatment guidelines, drug database, and glossary.
Resource updated 09/20/2023
Healthcare providers can receive no-cost expert clinical consultation in HIV prevention & care, HCV treatment, and substance use management.
Resource updated 09/20/2023
Federal guidelines for treatment, prevention and care of HIV disease, opportunistic infections, and common co-infections.
Resource updated 09/19/2023
Resource updated 08/26/2022
Resource updated 03/08/2024
Tool for service and program monitoring.
Resource updated 09/19/2023
Tool for service and program monitoring.
Resource updated 09/19/2023
Tool for service and program monitoring.
Resource updated 09/19/2023
Tool for service and program monitoring.
Resource updated 09/19/2023
Tool for service and program monitoring.
Resource updated 09/19/2023
Tool for service and program monitoring.
Resource updated 09/19/2023
Tool for service and program monitoring.
Resource updated 09/19/2023
Tool for service and program monitoring.
Resource updated 09/19/2023